Previous close | 0.0300 |
Open | 0.0100 |
Bid | 0.0100 |
Ask | 0.1300 |
Strike | 135.00 |
Expiry date | 2022-09-16 |
Day's range | 0.0100 - 0.1000 |
Contract range | N/A |
Volume | |
Open interest | 1.97k |
Novavax missed Wall Street expectations but remains optimistic about the fourth quarter and 2023.
A more than 30% peak decline in the Nasdaq Composite is allowing investors to buy these phenomenal stocks at bargain-basement prices.
(Bloomberg) -- The selloff in Novavax Inc. shares deepened on Tuesday, to erase $17 billion in market value from last year’s record high, after the Covid-19 vaccine maker slashed its revenue guidance.Most Read from BloombergMusk Sells $6.9 Billion of Tesla to Avoid Twitter Fire SaleUK Plans for Blackouts in January in Emergency Energy PlanTrump Under Intense Legal Scrutiny After FBI Searches Mar-a-LagoRussia Is Scouring the Globe for Weapons to Use Against UkraineTrump Search Was Unprecedented,